Abuse resistant opioid drug-ion exchange resin complexes having hybrid coatings
First Claim
Patent Images
1. A solid oral dose tablet, powder or granular formulation having modified release characteristics comprising at least one hybrid coated opioid-ion exchange resin complex and pharmaceutically acceptable excipients, said at least one hybrid coated opioid-ion exchange resin complex comprising:
- a pharmaceutically effective amount of an opioid bound to a pharmaceutically acceptable ion exchange resin; and
a cured hybrid modified release coating layer over the opioid-ion exchange resin complex, said hybrid coating comprising;
a pH-independent, high tensile strength, water insoluble, water-permeable, diffusion barrier coating forming component comprising about 70% to about 90% w/w polyvinylacetate (PVA) and about 3 to about 10% w/w of a plasticizer; and
an enteric coating forming component having pH-dependent solubility in an aqueous system which is non-reactive with said barrier coating forming component, said enteric coating forming component comprising polyvinylacetate phthalate,wherein said barrier coating forming component and said enteric coating forming component are present in a weight ratio of about 20;
1 to about 3;
1.
4 Assignments
0 Petitions
Accused Products
Abstract
A sustained release formulation for opioid drugs is described. The formulation contains an opioid-ion exchange resin complex having a hybrid coating. The hybrid coating contains a cured polyvinylacetate polymer and a pH-dependent enteric coating layer mixed therein. Also provided are methods of making and using same.
-
Citations
25 Claims
-
1. A solid oral dose tablet, powder or granular formulation having modified release characteristics comprising at least one hybrid coated opioid-ion exchange resin complex and pharmaceutically acceptable excipients, said at least one hybrid coated opioid-ion exchange resin complex comprising:
- a pharmaceutically effective amount of an opioid bound to a pharmaceutically acceptable ion exchange resin; and
a cured hybrid modified release coating layer over the opioid-ion exchange resin complex, said hybrid coating comprising; a pH-independent, high tensile strength, water insoluble, water-permeable, diffusion barrier coating forming component comprising about 70% to about 90% w/w polyvinylacetate (PVA) and about 3 to about 10% w/w of a plasticizer; and an enteric coating forming component having pH-dependent solubility in an aqueous system which is non-reactive with said barrier coating forming component, said enteric coating forming component comprising polyvinylacetate phthalate, wherein said barrier coating forming component and said enteric coating forming component are present in a weight ratio of about 20;
1 to about 3;
1. - View Dependent Claims (2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25)
- a pharmaceutically effective amount of an opioid bound to a pharmaceutically acceptable ion exchange resin; and
Specification